Drugs / TI-0010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06205524 | Jul 2023 → Dec 2024 | COVID-19 | National Drug Clinical Trial Institute of the Second Affiliated Hospital of Bengbu Medical College | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TI-0010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205524 ↗ |
| Modality | Vaccine | “TI-0010 is a novel lipid nanoparticles (LNP) -encapsulated circRNA-based vaccine targeting RBD of SARS-CoV-2.” NCT06205524 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT06205524 ↗ |